Immunological fluctuations during intrathecal immunotherapy in three patients affected by CNS tumours disseminating via CSF

International Journal of Neuroscience

Volumn 77, Issue 1-2, 1994, Pages 117-125

  Salmaggi, A ^a   Dufour, A ^a   Silvani, A ^a   Ciusani, E ^a   Nespolo, A ^a   Boiardi, A ^a  

^a DEPARTMENT OF NEUROSURGERY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; INTERLEUKIN 2; TUMOR NECROSIS FACTOR;

ADULT; ARTICLE; BRAIN TUMOR; CEREBELLUM; CEREBROSPINAL FLUID; DRUG THERAPY; FEMALE; GLIOBLASTOMA; HUMAN; IMMUNOLOGY; INTRASPINAL DRUG ADMINISTRATION; MALE; MEDULLOBLASTOMA; NATURAL KILLER CELL; PATHOLOGY; RADIOTHERAPY; THALAMUS;

ADULT; BRAIN NEOPLASMS; CEREBELLUM; DRUG THERAPY; FEMALE; GLIOBLASTOMA; HUMAN; INJECTIONS, SPINAL; INTERFERON-ALPHA; INTERLEUKIN-2; KILLER CELLS, NATURAL; MALE; MEDULLOBLASTOMA; RADIOTHERAPY; THALAMUS; TUMOR NECROSIS FACTOR;

EID: 0028476934     PISSN: 00207454     EISSN: None     Source Type: Journal    
DOI: 10.3109/00207459408986024     Document Type: Article

References (20)

1. Intraventricular interleukin-2 (IL-2)/lymphokine activated killer (LAK) cells for leptomeningeal metastases (LM) in pediatric brain tumors
2. Lymphokines and cytokines as cancer treatment: immunotherapy realized
3. Biological response modifiers: the new immunotherapy
4. Interleukin-2 (IL-2)-inducible lymphokine-activated killer (LAK) activity arising in blood following IL-2LAK therapy into the CSF compartment
5. Effect of interferon-gamma and tumor necrosis factor alpha on clonogenic growth of cell lines and primary cultures from human glioblastomas and brain metastasis
6. Cytokine responses to intraventricular injection of Interleukin 2 into patients with leptomeningeal carcinomatosis: rapid induction of Tumor Necrosis Factor α, Interleukin 1β, Interleukin-6, γ-Interferon, and soluble Interleukin 2 Receptor (Mr 55000 protein)
7. Immunobiology of primary intracranial tumors. Part 10: Therapeutic efficacy of interferon in the treatment of recurrent glioma
8. Treatment of recurrent malignant glioma by repeated intracerebral injection of human recombinant Interleukin-2 alone or in combination with systemic Interferon-α. Results of a phase I clinical trial
9. Delayed neurotoxicity of intraventricular interleukin-2: a case report
10. Clinical use of interferons in the treatment of malignant brain tumors
11. Systemic treatment with murine recombinant interleukin-1β inhibits the growth and progression of malignant glioma in the rat
12. The immunotherapy and gene therapy of cancer
13. The effect of human recombinant tumor necrosis factor on glioma-derived cell line, cellular proliferation, cytotoxicity, morphological and radioreceptor studies
14. Responses of human glioblastoma cells to human natural tumor nerosis factor-α: susceptibility, mechanism of resistence and cytokine production studies
15. Interleukin-2 bolus therapy induces immediate and selective disappearance from peripheral blood of all lymphocyte subpopulations displaying natural killer activity: role of cell adhesion to endothelium
16. Adhesion molecules on MHC-Nonrestricted lymphocytes: high density expression and role in oncolysis
17. A direct comparison of immunological and clinical effects of Interleukin-2 with and without Interferon-α in Humans
18. Natural killer function in flow cytometry. II Evaluation of NK lytic activity by means of target cell morphological changes detected by right angle light scatter
19. Effects of recombinant human tumor necrosis factor-α on the surface phenotype and the growth ogf human malignant glioma cell lines
20. Clinical effect of intra-arterial Tumor Necrosis Factor-α for malignant glioma